Format

Send to

Choose Destination
See comment in PubMed Commons below
Cardiovasc Intervent Radiol. 2016 Jul;39(7):1007-14. doi: 10.1007/s00270-016-1323-4. Epub 2016 Mar 10.

Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.

Author information

1
Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale University, 330 Cedar Street, TE 2-224, New Haven, CT, 06510, USA.
2
Department of Diagnostic Radiology, John Hopkins University School of Medicine, 601 N Caroline Street, Baltimore, MD, 21287, USA.
3
Interventional Radiology, Department of Radiology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
4
Division of Interventional Radiology, Department of Radiology, The University of Tennessee Health Science Center, 865 Jefferson Ave, Memphis, TN, 38103, USA.
5
Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale University, 330 Cedar Street, TE 2-224, New Haven, CT, 06510, USA. kevin.kim@yale.edu.
6
Yale Cancer Center, 333 Cedar Street, New Haven, CT, 06510, USA. kevin.kim@yale.edu.

Abstract

OBJECTIVE:

To investigate survival outcomes following radioembolization with Yttrium-90 (Y90) for neuroendocrine tumor liver metastases (NETLMs). This study was designed to assess the efficacy of Y90 radioembolization and to evaluate lung shunt fraction (LSF) as a predictor for survival.

METHODS:

A single-center, prospective study of 44 consecutive patients (median age: 58.5 years, 29.5 % male) diagnosed with pancreatic (52.3 %) or carcinoid (47.7 %) NETLMs from 2006 to 2012 who underwent Y90 radioembolization was performed. Patients' baseline characteristics, including LSF and median overall survival (OS) from first Y90 radioembolization, were recorded and compared between patients with high (≥10 %) and low (<10 %) LSF. Baseline comparisons were performed using Fisher's exact tests for categorical and Mann-Whitney U test for continuous variables. Survival was calculated using the Kaplan-Meier method. Univariate (Wilcoxon rank-sum test) and multivariate analyses (Cox Proportional Hazard Model) for risk factor analysis were performed.

RESULTS:

There was no statistically significant difference in age, gender, race, tumor properties, or previous treatments between patients with high (n = 15) and low (n = 29) LSF. The median OS was 27.4 months (95 %CI 12.73-55.23), with 4.77 months (95 %CI 2.87-26.73) for high and 42.77 months (95 %CI 18.47-59.73) for low LSF (p = 0.003). Multivariate analysis identified high LSF (p = 0.001), total serum bilirubin >1.2 mg (p = 0.016), and lack of pretreatment with octreotide (p = 0.01) as independent prognostic factors for poorer survival. Tumor type and total radiation dose did not predict survival.

CONCLUSIONS:

LSF ≥10 %, elevated bilirubin levels, and lack of pretreatment with octreotide were found to be independent prognostic factors for poorer survival in patients with NETLMs.

KEYWORDS:

Hepatopulmonary Shunt Fraction; Liver Metastases; Neuroendocrine Tumors; Survival Biomarker; Yttrium-90 Radioembolization

PMID:
26964779
DOI:
10.1007/s00270-016-1323-4
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center